TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35180010
Drug: Navitoclax (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (50 mg once daily, escalating to a maximum of 300 mg once daily)
Study: 35180010
Drug: Ruxolitinib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (≥ 10 mg twice daily)
Study: 35180323
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and vorinostat with FLAG chemotherapy (fludarabine, cytarabine, and G-CSF)
Study: 35180323
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and vorinostat with FLAG chemotherapy
Study: 35180771
Drug: E7389-LF 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 2.0 mg/m2 Q3W
Study: 35180771
Drug: E7389-LF 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 1.5 mg/m2 Q2W
Study: 35180771
Drug: E7389-LF 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W
Study: 35181266
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SPPB and MoCA
Study: 35181266
Drug: Nottingham Extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nottingham Extended Activities of Daily Living (IADL)
Study: 35181498
Drug: Rezivertinib (BPI-7711)
Normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezivertinib (BPI-7711) at doses of 30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg once daily until disease progression, unacceptable toxicity, or patient withdrawal
Study: 35181499
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg once daily) plus durvalumab (3 or 10 mg/kg every 2 weeks) in part A
Study: 35181499
Drug: Osimertinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib plus durvalumab (10 mg/kg every 2 weeks) in part B
Study: 35181700
Drug: Optimal set
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal set of biomarkers selected by LASSO (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, transferrin receptor protein-1, chitotriosidase-1)
Study: 35182224
Drug: G-atezo-pola (obinutuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.4 mg/kg
Study: 35182224
Drug: G-atezo-pola (obinutuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.8 mg/kg
Study: 35182224
Drug: G-atezo-pola
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-atezo-pola
Study: 35182741
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) for hepatitis C
Study: 35183167
Drug: Benralizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab therapy
Study: 35183221
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of concurrent chemotherapy (CC)
Study: 35183221
Drug: Accumulated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accumulated dose of cisplatin < 200 mg
Study: 35185515
Drug: Home-based transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based transcranial direct current stimulation (tDCS) administered by study companions, 37 sessions over 12 weeks.
Study: 35185515
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program for study companions to administer tDCS remotely.
Study: 35185746
Drug: Digital Dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Dance for PD (10-h weekly sessions)
Study: 35186675
Drug: Combined metabolic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metabolic surgery (gastric bypass) plus medical therapy (CSM)
Study: 35186675
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (MTA)
Study: 35187036
Drug: DGA-conforming diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGA-conforming diet (DGAD) with 240 g/wk of salmon and albacore tuna
Study: 35187383
Drug: intramuscular low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intramuscular low-dose testosterone
Study: 35187951
Drug: Palbociclib, Letrozole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib, Letrozole, and Venetoclax combination therapy
Study: 35187951
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with a CDK4/6 inhibitor (gold standard treatment)
Study: 35190519
Drug: Apatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib plus temozolomide (temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle)
Study: 35190653
Drug: Radium-223 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 treatment
Study: 35191018
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg /1·5 mL subcutaneously at weeks 0, 1, 2, 4 and every 2 weeks thereafter
Study: 35191428
Drug: CYAD-101 (NKG2D-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYAD-101 (NKG2D-based CAR T-cell therapy)
Study: 35192686
Drug: Inpatient chemotherapy
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient chemotherapy
Study: 35192686
Drug: Antibiotic pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic pressure reduction
Study: 35193825
Drug: Sibling cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibling cord blood cell infusion (12/12 HLA-matched)
Study: 35193905
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment in the public health system of the Maule Region, Chile
Study: 35193932
Drug: Toripalimab 1
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally two times per day
Study: 35194187
Drug: Standard-of-care genotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care genotoxic radio-chemotherapy
Study: 35195562
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with full dose systemic chemotherapy; SBRT dosing: 60 Gy in 3 fractions for peripheral tumors, 50 Gy in 5 fractions for central tumors, 40-50 Gy in 5 fractions for hilar/mediastinal lymph nodes; Chemotherapy: 4 cycles of pemetrexed and cisplatin or carboplatin and paclitaxel for nonsquamous histology; cisplatin and docetaxel or cisplatin and paclitaxel for squamous histology; SBRT given between chemotherapy cycles with a 7-day break.
Study: 35195837
Drug: Varlitinib combined
Normalized name: Varlitinib
DrugBank: Varlitinib (DB05944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlitinib combined with paclitaxel (300 mg twice daily intermittently dosed)
Study: 35196021
Drug: Cytokine-induced memory-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine-induced memory-like (ML) NK cells stimulated with interleukin-12 (IL-12), IL-15, and IL-18.
Study: 35196370
Drug: Ibrutinib plus
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d])
Study: 35196395
Drug: 15-min intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min intravenous infusion of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Study: 35196395
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Study: 35196871
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate inhalation solution (30 mg, 60 mg, 90 mg, 120 mg, and 120 mg with saccharin)
Study: 35196871
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate inhalation solution (120 mg with saccharin)
Study: 35198648
Drug: Tocilizumab administration
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab administration
Study: 35199231
Drug: High anti-HPV16
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High anti-HPV16 L1 antibody titers
Study: 35199492
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (monotherapy)
Study: 35199944
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hypertension (having taken antihypertensives in the past 2 weeks)
Study: 35199944
Drug: Control of
Normalized name: A replication-competent adenovirus type 5 in which the E1A and E1B genes are under the control of a human telomerase reverse transcriptase (hTERT) and IRES, respectively.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control of hypertension (taking antihypertensives and having BP < 140/90 mmHg)
Study: 35200588
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor
Study: 35201621
Drug: Mifamurtide combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifamurtide combined with high-dose ifosfamide (HDIFO) for poor responders (PRs) after high-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Study: 35201621
Drug: High-dose methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Study: 35203258
Drug: Innovative therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative therapeutic schemes and drugs
Study: 35205346
Drug: Copper tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper tolerance treatment
Study: 35210307
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks for ≤2 years)
Study: 35210531
Drug: Intravenous 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS group)
Study: 35210531
Drug: Intravenous 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (PCS group)
Study: 35210531
Drug: Intravenous 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS and PCS groups)
Study: 35210606
Drug: mRNA-HB27-LNP; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-HB27-LNP; administered intravenously; single prophylactic administration.
Study: 35210606
Drug: mRNA-HB27-LNP; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-HB27-LNP; administered prophylactically in a close contact transmission model.
Study: 35211080
Drug: MyoPro™ orthosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyoPro™ orthosis used in motor learning-based therapy
Study: 35212017
Drug: Just-in-time adaptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Just-in-time adaptive interventions (JITAIs) during cognitive-behavioral therapy (CBT-E)
Study: 35212017
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT-E) without JITAIs
Study: 35212470
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug use and no experience of violence with ART
Study: 35212470
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use and experience of violence
Study: 35212486
Drug: GLA gene
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA gene variant c.376A>G (p.Ser126Gly)
Study: 35212640
Drug: Vaccine-promoting intervention
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-promoting intervention for vaccine hesitancy reduction
Study: 35212779
Drug: Crenolanib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenolanib (oral, once daily)
Study: 35218024
Drug: Neural network
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural network predicted rectal dose for patients with rectal spacer insertion
Study: 35221224
Drug: Whole-body insulin
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body insulin clearance
Study: 35221224
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity (M value)
Study: 35221650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pectoral type 1 (PECS I) and serratus plane block (SPB)
Study: 35221928
Drug: Heterotopic Ossification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterotopic Ossification treatment, specific details not available
Study: 35222036
Drug: SHR2285, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285, a small-molecule Factor XIa inhibitor
Study: 35222248
Drug: EVT after
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT after IV alteplase (combination-therapy group)
Study: 35222719
Drug: Alprostadil treatment
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil treatment (Group A, n=52)
Study: 35222719
Drug: Alprostadil plus
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil plus hyperbaric oxygen (HBO) treatment (Group B, n=52)
Study: 35223458
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20)
Study: 35223458
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg every 12 hours in combination with anastrozole (Part B, n=16)
Study: 35223458
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg every 12 hours in combination with tamoxifen (Part C, n=16)
Study: 35223458
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg every 12 hours in combination with exemestane (Part D, n=15)
Study: 35223882
Drug: Initial photodynamic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Study: 35223882
Drug: Delayed photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed photodynamic therapy (PDT) with intravitreal injection of conbercept (IVC)
Study: 35224534
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of linguistic and acoustic features in semi-structured conversations
Study: 35226112
Drug: Sorafenib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib treatment for advanced HCC
Study: 35227313
Drug: Telmisartan 40 mg/S-amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg/S-amlodipine 2.5 mg
Study: 35227313
Drug: Telmisartan 80 mg
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80 mg
Study: 35229612
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulant (DOAC) use in patients with MHCs
Study: 35229827
Drug: Fractionated proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated proton radiation therapy (FPRT) to a total dose of 50.4 to 54 Gy RBE over 28 to 30 fractions
Study: 35230138
Drug: Closed-Loop Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
Study: 35230165
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid use in women living with HIV
Study: 35230165
Drug: Prescription opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription opioid use in women without HIV
Study: 35230254
Drug: Telemonitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring with antihypertensive treatment titration
Study: 35230974
Drug: Targeting collagens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeting collagens that signal through LAIR-1 in combination with blockade of TGF-β and PD-L1
Study: 35232419
Drug: Interleukin-1 Receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-1 Receptor antagonist (IL-1Ra) measured in serum levels during 6 months follow-up.
Study: 35234658
Drug: Self-monitoring intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-monitoring intervention using composite web-based multidimensional PA feedback with real-time daily feedback
Study: 35234887
Drug: DPP Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP Group Lifestyle Balance (GLB) program delivered via face-to-face groups or DVD with weekly telephonic coach contact
Study: 35235414
Drug: Immune Checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune Checkpoint Inhibition as Single Therapy
Study: 35235412
Drug: CDK 4/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK 4/6 inhibitors plus endocrine therapy
Study: 35235572
Drug: Benzodiazepines <1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines <1 mg/day
Study: 35235572
Drug: Benzodiazepines >2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines >2.5 mg/day
Study: 35235572
Drug: Specific benzodiazepine
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific benzodiazepine agents
Study: 35236302
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) for 8 weeks (1500-3000 mg total daily dose)
Study: 35236302
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC) for 8 weeks (1500-6500 mg total daily dose) followed by LC for 8 weeks (1500-3000 mg total daily dose)
Study: 35236302
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (LC) for up to 6 months (1500-3000 mg total daily dose)
Study: 35237053
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg every 12 h for 5-7 days
Study: 35237053
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 24 h for 5-7 days
Study: 35237748
Drug: Nitazoxanide 600
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 600 mg twice daily for five days
Study: 35238467
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy recommended by the Molecular Tumor Board (MTB)
Study: 35238615
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture during chemotherapy infusion
Study: 35239543
Drug: Pain medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication, preoperative anxiety, postoperative nausea and vomiting, and parent satisfaction were analyzed.
Study: 35239732
Drug: Ferric citrate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric citrate, initial dose adjusted to maintain serum phosphorus at 3.5-5.5 mg/dL, mean dose of 3.35±1.49 g/day (range 1.5 to 6.0 g/day)
Study: 35241141
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) at a dose of 2×10^6 cells
Study: 35241141
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs)
Study: 35241151
Drug: Human umbilical
Normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human umbilical cord MSCs injected twice into the uterus
Study: 35241226
Drug: Therapeutic-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose enoxaparin
Study: 35241240
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (HT) in females aged ≥60 years (N = 2,153, 47.6%)
Study: 35241644
Drug: Branaplam, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branaplam, an orally available, brain penetrant small molecule
Study: 35241844
Drug: 50 µg booster
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg booster injection of mRNA-1273
Study: 35241942
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (controlled-release 10 mg every 12 hours and immediate-release 5 mg every 4 hours as needed)
Study: 35241942
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol (controlled-release 100 mg every 8 hours and immediate-release 50 mg every 4 hours as needed)
Study: 35242683
Drug: Neoadjuvant pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pyrotinib 400 mg once daily, trastuzumab 4 mg/kg loading dose followed by 2 mg/kg once a week, and albumin-bound paclitaxel 125 mg/m2.